The global glaucoma therapeutics market size was estimated to be USD 7.98 billion in 2023 and is expected to reach at USD 15.91 billion by 2034 with a CAGR of 6.48% during the forecast period 2024-2034. Growing geriatric population, increasing prevalence of glaucoma, rising improvements in diagnostic tools for the early detection of glaucoma, surge in adoption of prostaglandin analogues, growing launch of advanced products, increasing approvals by regulatory bodies, rising focus on development of advanced glaucoma diagnostic methods, and regulatory organizations are increasingly approving innovative products are some of the key factors boosting the market growth.
Regulatory organizations are increasingly approving innovative products is predicted to boost the market growth during the forecast period. Growing research in prostaglandin analogs has led to a change in preference among glaucoma patients, who are increasingly opting for this drug category. This class of drugs offers improved effectiveness and reduced side effects in comparison to alternative treatment choices and therapeutic items. For instance, in December 2022, Thea Pharma announced that the FDA has given its approval to Iyuzeh, an eye drop solution that contains latanoprost, intended for the treatment of ocular hypertension.
By drug class, prostaglandins analogs was the highest revenue-grossing segment in the global glaucoma therapeutics market in 2023 owing to its ability to lower intraocular pressure (IOP) & its relative lack of negative effects compared to other treatments and growing product approvals by regulatory bodies. For instance, in December 2022, The FDA has granted approval to Iyuzeh (0.005% latanoprost ophthalmic solution) for lowering elevated intraocular pressure (IOP) in patients who have open-angle glaucoma or ocular hypertension. Additionally, combination drugs is predicted to grow at fastest CAGR during the forecast period owing to the increasing research & development activities and rising focus on development of effective drugs.
By indication, open angle glaucoma was the highest revenue-grossing segment in the global glaucoma therapeutics market in 2023 owing to the availability of advanced treatment drugs for open angle glaucoma, increasing prevalence of glaucoma disorder, and rising regulatory approvals of advanced products. For instance, in October 2022, Santen has disclosed that the FDA has granted approval for OMLONTI, their latest ophthalmic medication. This medication is designed to reduce intraocular pressure (IOP) in individuals diagnosed with ocular hypertension or open-angle glaucoma. Additionally, angle closure glaucoma is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of eye related disorders and rising advancements in treatment of eye disorders.
By distribution channel, hospital pharmacy was the highest revenue-grossing segment in the global glaucoma therapeutics market in 2023 owing to the convenient setting of a hospital pharmacy, patients may readily access specialist treatment, rising patient preference for receiving care in outpatient settings, especially among the elderly, and increasing collaborations within market players. For instance, In March 2022, Oculis S.A., a worldwide organization dedicated to ophthalmology research and advancements in eye care, and Accure Therapeutics, a company specializing in translational neuroscience research and development, have disclosed a licensing arrangement. This agreement pertains to the development and distribution of ACT-01, a prospective therapeutic approach designed to potentially modify diseases by safeguarding the optic nerve and retina. Additionally, online pharmacy is predicted to grow at fastest CAGR during the forecast period owing to the easy access to a wide range of medications at reasonable prices, increasing adoption of a straightforward & practical substitute for purchasing prescription medicines, and growing demand for home delivery services.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in number of dry eye patients, rising prevalence of eye diseases, growing advancements in research & development, surge in healthcare infrastructure, and increasing focus on development of innovative products. For instance, in December 2022, According to a press release from Visiox Pharma, the FDA has given its approval to a new drug application for PDP-716, intended for treating glaucoma. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing introduction of new drugs, rising investment by major market players for research, surge in awareness initiatives by government organizations regarding the disease, and growing mergers & acquisition within market players. For instance, in August 2022, Alcon has purchased Aerie Pharmaceuticals, a manufacturer of glaucoma medications, for $770 million, expecting that its extensive commercial network will drive the sales of Aerie's two drugs. This acquisition provides Alcon with two glaucoma drugs that are already on the market and a series of other eye disease programs in development. Alcon has been actively engaged in mergers and acquisitions with the goal of strengthening its eye product portfolio and pipeline. The acquisition price amounts to $15.25 per share for Aerie, representing a 37% premium over its closing stock price.
Regulatory organizations are increasingly approving innovative products is predicted to boost the market growth during the forecast period. Growing research in prostaglandin analogs has led to a change in preference among glaucoma patients, who are increasingly opting for this drug category. This class of drugs offers improved effectiveness and reduced side effects in comparison to alternative treatment choices and therapeutic items. For instance, in December 2022, Thea Pharma announced that the FDA has given its approval to Iyuzeh, an eye drop solution that contains latanoprost, intended for the treatment of ocular hypertension.
By drug class, prostaglandins analogs was the highest revenue-grossing segment in the global glaucoma therapeutics market in 2023 owing to its ability to lower intraocular pressure (IOP) & its relative lack of negative effects compared to other treatments and growing product approvals by regulatory bodies. For instance, in December 2022, The FDA has granted approval to Iyuzeh (0.005% latanoprost ophthalmic solution) for lowering elevated intraocular pressure (IOP) in patients who have open-angle glaucoma or ocular hypertension. Additionally, combination drugs is predicted to grow at fastest CAGR during the forecast period owing to the increasing research & development activities and rising focus on development of effective drugs.
By indication, open angle glaucoma was the highest revenue-grossing segment in the global glaucoma therapeutics market in 2023 owing to the availability of advanced treatment drugs for open angle glaucoma, increasing prevalence of glaucoma disorder, and rising regulatory approvals of advanced products. For instance, in October 2022, Santen has disclosed that the FDA has granted approval for OMLONTI, their latest ophthalmic medication. This medication is designed to reduce intraocular pressure (IOP) in individuals diagnosed with ocular hypertension or open-angle glaucoma. Additionally, angle closure glaucoma is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of eye related disorders and rising advancements in treatment of eye disorders.
By distribution channel, hospital pharmacy was the highest revenue-grossing segment in the global glaucoma therapeutics market in 2023 owing to the convenient setting of a hospital pharmacy, patients may readily access specialist treatment, rising patient preference for receiving care in outpatient settings, especially among the elderly, and increasing collaborations within market players. For instance, In March 2022, Oculis S.A., a worldwide organization dedicated to ophthalmology research and advancements in eye care, and Accure Therapeutics, a company specializing in translational neuroscience research and development, have disclosed a licensing arrangement. This agreement pertains to the development and distribution of ACT-01, a prospective therapeutic approach designed to potentially modify diseases by safeguarding the optic nerve and retina. Additionally, online pharmacy is predicted to grow at fastest CAGR during the forecast period owing to the easy access to a wide range of medications at reasonable prices, increasing adoption of a straightforward & practical substitute for purchasing prescription medicines, and growing demand for home delivery services.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in number of dry eye patients, rising prevalence of eye diseases, growing advancements in research & development, surge in healthcare infrastructure, and increasing focus on development of innovative products. For instance, in December 2022, According to a press release from Visiox Pharma, the FDA has given its approval to a new drug application for PDP-716, intended for treating glaucoma. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing introduction of new drugs, rising investment by major market players for research, surge in awareness initiatives by government organizations regarding the disease, and growing mergers & acquisition within market players. For instance, in August 2022, Alcon has purchased Aerie Pharmaceuticals, a manufacturer of glaucoma medications, for $770 million, expecting that its extensive commercial network will drive the sales of Aerie's two drugs. This acquisition provides Alcon with two glaucoma drugs that are already on the market and a series of other eye disease programs in development. Alcon has been actively engaged in mergers and acquisitions with the goal of strengthening its eye product portfolio and pipeline. The acquisition price amounts to $15.25 per share for Aerie, representing a 37% premium over its closing stock price.
Segmentation: Glaucoma Therapeutics Market Report 2022 - 2033
Glaucoma Therapeutics Market Analysis & Forecast by Drug Class 2023 - 2034 (Revenue USD Bn)
- Beta Blockers
- Prostaglandins Analogs
- Latanoprost
- Bimatoprost
- Travoprost
- Others
- Alpha Adrenergic Agonists
- Carbonic Anhydrase Inhibitors
- Combination Drugs
- Others
Glaucoma Therapeutics Market Analysis & Forecast by Indication 2023 - 2034 (Revenue USD Bn)
- Angle Closure Glaucoma
- Open Angle Glaucoma
- Others
Glaucoma Therapeutics Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Glaucoma Therapeutics Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Glaucoma Therapeutics Market: Drug Class Estimates & Trend Analysis
8. Glaucoma Therapeutics Market: Indication Estimates & Trend Analysis
9. Glaucoma Therapeutics Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Glaucoma Therapeutics Market
12. Europe Global Glaucoma Therapeutics Market
13. Asia Pacific Global Glaucoma Therapeutics Market
14. Latin America Global Glaucoma Therapeutics Market
15. MEA Global Glaucoma Therapeutics Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Akron Operating Company LLC
- Pfizer Inc.
- AbbVie Inc.
- Visiox Pharma
- Novartis AG
- Teva Pharmaceuticals Industries Ltd.
- Thea Pharma
- Aerie Pharmaceuticals Inc.
- Bausch + Lomb Corporation
- Alcon Inc.
- Santen Pharmaceutical Co. Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 7.98 Billion |
| Forecasted Market Value ( USD | $ 15.91 Billion |
| Compound Annual Growth Rate | 6.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
